Léa Ousset,Alban Canali,Barbara J Bain
Léa Ousset
Case Reports
American journal of hematology. 2026 Jul 3. DOI:10.1002/ajh.70437 2026
Undetectable Hydroxyurea Levels in the Majority of Sickle Cell Disease Patients, Especially in Young Children [0.03%]
多数镰状细胞病患者血液中羟基脲水平无法检出，尤其是年轻儿童患者
Sigrid van der Veen,Bart J Biemond,Marjon H Cnossen et al.
Sigrid van der Veen et al.
Hydroxyurea (HU) is the most widely prescribed disease-modifying treatment in sickle cell disease (SCD), though treatment responses vary due to metabolism and adherence. We examined HU blood levels and treatment response in patients with ho...
Myelodysplastic Syndromes: 2026 Update on Diagnosis, Risk-Stratification and Management [0.03%]
低恶性骨髓疾病诊断、分险评估及治疗最新进展（2026更新版）
Guillermo Garcia-Manero
Guillermo Garcia-Manero
Disease overview: The myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid disorders characterized by peripheral blood cytopenias and increased risk of transformation to acute myelogenous leukemia (AML). M...
Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMA [0.03%]
FLT3和/或IDH突变抵消了NPM1突变在老年急性髓系白血病患者初治中使用维奈克拉联合地西他滨中的有利作用
Fieke W Hoff,Joshua F Zeidner,Geeta Torlapati et al.
Fieke W Hoff et al.
Frameshift mutations in exon 12 of nucleophosmin 1 (NPM1mut) are among the most common mutations in acute myeloid leukemia (AML) and have historically been considered favorable-risk in the absence of FLT3-ITD. In the European LeukemiaNet (E...
Comparative Efficacy of Intranasal, Intramuscular, and Intravenous Vitamin B12 Therapy for Hematological Recovery in Vitamin B12 Deficiency Anemia: A Randomized Controlled Trial [0.03%]
维生素B12缺乏性贫血患者血象恢复的 Comparative Efficacy of Intranasal, Intramuscular, and Intravenous Vitamin B12 Therapy for Hematological Recovery in Vitamin B12 Deficiency Anemia: A Randomized Controlled Trial肌内注射、鼻内给药和静脉输注维生素B12疗效的随机对照试验
Santosh Kumar Singh,Rahil Arora,Suman Kumar Pramanik et al.
Santosh Kumar Singh et al.
Vitamin B12 deficiency causes megaloblastic anemia and ineffective hematopoiesis. While intramuscular administration remains standard, intravenous and intranasal alternatives are increasingly used. Rigorous comparative data on hematological...
Clinical Predictors of Response in Chronic Graft-Versus-Host Disease: Results From the "Predicting the Quality of Response to Specific Treatments (PQRST)" Trial [0.03%]
慢性移植物抗宿主病临床疗效预测因素：“特定治疗方案的疗效质量预测（PQRST）”试验结果
Betty K Hamilton,Lynn Onstad,Paul A Carpenter et al.
Betty K Hamilton et al.
Despite significant progress in chronic GVHD therapies, challenges remain in understanding pleomorphic phenotypes and varying responses to treatment. The aim of this study was to identify predictors of treatment response. We conducted a pro...
Relapse Thresholds (12/24 Mo) Define Survival Disparity in Pediatric B-ALL [0.03%]
复发阈值（12/24个月）定义了儿童B-ALL的生存差异
Binjun Xiong,Jianwen Zhou,Xuhan Zhang et al.
Binjun Xiong et al.
This study systematically analyzed relapse patterns in pediatric B-cell acute lymphoblastic leukemia (B-ALL) across 2930 patients from the TARGET and MP2PRT cohorts, with an additional 2972 patients from four independent external validation...
Quizartinib in Combination With FLAG-IDA for Relapsed or Refractory Acute Myeloid Leukemia (FLAG-QUIDA): A PETHEMA Phase I-II Trial [0.03%]
氟达拉滨、阿糖胞苷和 ida联合 quizartinib治疗复发或难治急性髓系白血病（FLAG-QUIDA）：PETHEMA Ⅰ/Ⅱ期临床试验结果
Teresa Bernal,Javier Zambrano Márquez,Rebeca Rodríguez-Veiga et al.
Teresa Bernal et al.
Quizartinib is a tyrosine kinase inhibitor with single agent activity in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) and has demonstrated efficacy in first-line therapy when combined with intensive chemotherapy i...
Defining a Subgroup of Myelodysplastic Syndrome Patients With Very Poor-Risk Cytogenetics Demonstrating a Relatively More Favorable Outcome After Allogeneic Hematopoietic Cell Transplantation [0.03%]
定义一组细胞遗传学上高危的骨髓增生异常综合征患者，在异基因造血细胞移植后预后相对较好
Xavier Poiré,Dirk-Jan Eikema,Linda Koster et al.
Xavier Poiré et al.
Safety and Efficacy of Plerixafor in Poor Mobilizers With Lymphoma: A Multicenter, Prospective, Single-Arm Study [0.03%]
评价plerixafor在自体干细胞动员不良的淋巴瘤患者中疗效和安全性的多中心前瞻性单组研究
Meng Wu,Mingxing Zhong,Hongmei Jing et al.
Meng Wu et al.